A senior doctor from AIIMS Delhi has publicly criticised the wearable device that Zomato CEO Deepinder Goyal has been seen wearing, saying it currently has zero scientific credibility as a health tool.
Dr Suvrankar Datta, a radiologist and researcher trained at AIIMS, took to X to question the science behind what Goyal calls the Temple device. According to the doctor, this experimental brain-flow wearable doesn’t have the backing of established science and is not proven to be medically useful.
Doctor says Temple device lacks scientific support
Dr Datta said the device is, at this stage, what he called a “fancy toy for billionaires” that lacks real scientific validation. He warned the public not to spend their hard-earned money on gadgets with no proven medical value.
He posted on X:
“As a physician-scientist and one of the earliest researchers in arterial stiffness and pulse wave velocity (2017), which predicts cardiovascular mortality, I can assure you that this device currently has zero scientific standing as a useful device and do not waste your hard-earned money to buy fancy toys billionaires can afford to waste money on.”
What the Temple wearable claims to do:
Goyal has described the Temple device as an experimental wearable sensor designed to measure cerebral blood flow in real time and continuously. He has also linked the idea to broader theories on ageing and longevity, including a suggestion that gravity may affect how the human body ages.
The gadget first grabbed attention when Goyal wore a version of it during a recent podcast appearance. Social media users later spotted him wearing another version near his right eye during past public events.
The project is being developed under Goyal’s research venture Continue Research, part of the larger group that includes Zomato’s parent company. He has reportedly invested a significant amount of his own wealth into the initiative.
Many medical professionals say devices claiming to measure complex biological signals should go through rigorous clinical testing before they’re promoted for wider use. In medicine, wearables must be validated through controlled studies and trials before they can be trusted by the public.
Dr Datta echoed this point, emphasising that while experimentation and curiosity are fine, promotional claims need backing by solid research. Without that, he said, such gadgets remain speculative and not ready for everyday users.
As of now, the Temple device is still experimental. It’s not available for public sale, and there’s no published clinical evidence proving it can reliably monitor cerebral blood flow or influence health outcomes.
The debate around this gadget underscores a wider issue like how to balance enthusiasm for new wearable health technology with the need for rigorous scientific checks. For users curious about brain health wearables, experts advise waiting for clear proof before buying into claims.
– Ends
